Ascelia Pharma AB (publ) (OM: ACE)
Health Care · Biotechnology · SE
Skr0.61
+6.09% today · -87.0% 1Y
Ascelia Pharma AB (publ) (OM: ACE) operates in the Biotechnology industry within the Health Care sector. The company is valued at $8.60M and employs 10 people.
Over the last twelve months the share price has lost 87.0%, trading between 0.46 and 5.13.
Tweenvest scores Ascelia Pharma AB (publ) across four factors: quality 26/100. Its strongest factor is quality.
ACE price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $8.60M
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -0.48
- Dividend yield
- —
- Beta (5Y)
- 0.84
- 52-week high
- Skr5.13
- 52-week low
- Skr0.46
- Avg volume (3M)
- —
- Shares outstanding
- 133.54M
- Employees
- 10
- Next earnings
- —
About Ascelia Pharma AB (publ)
Ascelia Pharma AB (publ) is a Swedish biotechnology company concentrating on the development of orphan drugs for cancer treatment. The firm is currently progressing Mangoral, an innovative non-gadolinium contrast agent, through Phase 3 clinical trials for magnetic resonance imaging (MRI) of the liver. Furthermore, it is advancing Oncoral, a novel oral chemotherapy tablet, which is in Phase 2 development for gastric cancer therapy. Ascelia Pharma has also entered into a clinical collaboration agreement with Taiho Oncology, Inc. to develop Oncoral in combination with LONSURF. The company was established in 2000 and has its headquarters situated in Malmö, Sweden.
- ISIN
- SE0010573113
- Founded
- 1999
- Listed since
- Mar 13, 2019
- Exchange
- OMX Nordic Exchange Stockholm
- Currency
- SEK
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $468.22B | $264.96 | +1.20% |
| Amgen Inc.NasdaqGS: AMGN | $237.52B | $439.33 | +1.29% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.18B | $146.12 | +1.86% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.91B | $548.05 | +1.44% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.28B | $834.04 | +0.90% |
| argenx SEENXTBR: ARGX | $65.85B | €902.00 | +1.90% |
| Moderna, Inc.NasdaqGS: MRNA | $57.92B | $145.13 | +0.04% |
| CSL LimitedASX: CSL | $57.77B | AU$168.30 | -1.69% |
Figures last refreshed Aug 18, 2026.